Atara Biotherapeutics Inc. (NASDAQ:ATRA) was downgraded by equities research analysts at Goldman Sachs Group Inc. from a “neutral” rating to a “sell” rating in a report released on Thursday. They presently have a $16.00 price target on the stock, down from their prior price target of $23.00. Goldman Sachs Group Inc.’s price target indicates a potential downside of 17.10% from the stock’s current price.

ATRA has been the subject of a number of other research reports. Jefferies Group reiterated a “buy” rating and set a $25.00 price target on shares of Atara Biotherapeutics in a research note on Sunday, July 10th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 19th. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, June 7th. Citigroup Inc. lifted their price target on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research note on Friday, August 19th. Finally, JMP Securities reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $26.14.

Atara Biotherapeutics (NASDAQ:ATRA) opened at 19.30 on Thursday. Atara Biotherapeutics has a 52-week low of $13.31 and a 52-week high of $49.94. The stock has a 50 day moving average price of $21.94 and a 200 day moving average price of $19.93. The firm’s market cap is $556.05 million.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. Equities analysts predict that Atara Biotherapeutics will post ($2.85) earnings per share for the current fiscal year.

In related news, insider Christopher Haqq sold 1,346 shares of Atara Biotherapeutics stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $22.32, for a total value of $30,042.72. Following the sale, the insider now owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 9,600 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, July 8th. The stock was sold at an average price of $22.88, for a total transaction of $219,648.00. Following the completion of the sale, the chief executive officer now directly owns 223,228 shares in the company, valued at approximately $5,107,456.64. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of ATRA. Schwab Charles Investment Management Inc. boosted its stake in Atara Biotherapeutics by 24.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 66,295 shares of the company’s stock worth $1,493,000 after buying an additional 13,020 shares during the period. Redmile Group LLC boosted its stake in Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock worth $54,226,000 after buying an additional 133,205 shares during the period. Metropolitan Life Insurance Co. NY boosted its stake in Atara Biotherapeutics by 48.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,716 shares of the company’s stock worth $399,000 after buying an additional 5,756 shares during the period. Slate Path Capital LP bought a new stake in Atara Biotherapeutics during the second quarter worth approximately $9,454,000. Finally, Barclays PLC boosted its stake in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the period. 75.50% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.